circMRPS35 promotes malignant progression and cisplatin resistance in hepatocellular carcinoma
Peng Li,Runjie Song,Fan Yin,Mei Liu,Huijiao Liu,Shuoqian Ma,Xiaomeng Jia,Xiaohui Lu,Yuting Zhong,Lei Yu,Xiru Li,Xiangdong Li
DOI: https://doi.org/10.1016/j.ymthe.2021.08.027
IF: 12.91
2022-01-01
Molecular Therapy
Abstract:Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related death worldwide. Circular RNAs (circRNAs), a novel class of non-coding RNA, have been reported to be involved in the etiology of various malignancy. However, the underlying cellular mechanisms of circRNAs implicated in the pathogenesis of HCC remains unknown. Here, we identified a functional RNA - hsa_circ_0000384 (circMRPS35) from public tumor databases using a set of computational analyses, and we further identified that circMRPS35 was highly expressed in 35 pairs of HCC from patients. Moreover, knockdown the expression of circMRPS35 in Huh-7 and HCC-LM3 cells suppressed their proliferation, migration, invasion, clone formation and cell cycle in vitro, and suppressed tumor growth in vivo as well. Mechanically, circMRPS35 sponged microRNA-148a-3p (miR-148a) regulating the expression of Syntaxin 3 (STX3), which modulated the ubiquitination and degradation of Phosphatase and tensin homolog (PTEN). Unexpectedly, we detected a peptide encoded by circMRPS35 (circMRPS35-168aa), which was significantly induced by chemotherapeutic drugs and promoted cisplatin resistance in HCC. These results demonstrated that circMRPS35 might be a novel mediator in HCC progress, and raise the potential as a new biomarker for HCC diagnosis and prognosis, as well as a novel therapeutic target for HCC patients.
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology